Baird on Axsome Therapeutics (AXSM): 'Incrementally positive on regulatory updates'

Baird analyst Joel Beatty reiterated an Outperform rating and $157.00 price target on Axsome Therapeutics (NASDAQ: AXSM).

The analyst comments "Incrementally positive on regulatory updates. Axsome announced two New Year's Eve regulatory updates, with their sNDA for AXS-05 (Auvelity) in Alzheimer's agitation accepted by the FDA with priority review and given a PDUFA date of April 30, 2026. Additionally, following receipt of meeting minutes from their pre-NDA meeting with the FDA, Axsome expects to submit the NDA for AXS-12 for treatment of cataplexy in narcolepsy. These developments set up two potential approvals in 2026 to add to the building momentum of Axsome's commercial franchises."

For an analyst ratings summary and ratings history on Axsome Therapeutics click here. For more ratings news on Axsome Therapeutics click here.

Shares of Axsome Therapeutics closed at $148.79 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Phillips 66, Marathon Merger Talks Collapsed - Semafor